Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 8/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4791334 | 0.93 | NAMPT (0.47) | NAMPTPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL3199773 | 0.93 | NAMPT (0.49) | NAMPTPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL3738335 | 0.90 | PIK3CA (0.47) | NAMPTPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL4721274 | 0.88 | FAAH (0.44) | NAMPTCHRM1HTR2AMCHR1NPSR1 | |
| SCHEMBL4709225 | 0.87 | NAMPT (0.43) | NAMPTCHRM1HTR2AMCHR1NPSR1 | |
| SCHEMBL3731808 | 0.86 | CHRM3 (0.47) | NAMPTCHRM1HTR2AMCHR1NPSR1 | |
| SCHEMBL3731440 | 0.86 | NAMPT (0.43) | NAMPTPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3731821 | 0.86 | NAMPT (0.51) | NAMPT | |
| Hydrochloric Acid SCHEMBL3738405 | 0.86 | CHRM3 (0.46) | NAMPTCHRM1HTR2AMCHR1NPSR1 | |
| Hydrochloric Acid SCHEMBL3733524 | 0.86 | CHRM3 (0.46) | NAMPTCHRM1HTR2AMCHR1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825120-B2 | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas | CYTOKINETICS, INC. (US) | 2010-11-02 | — | — | US | claimed |
| EP-1959960-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| EP-1959963-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| US-20070197504-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007089336-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-08-09 | — | — | WO | claimed |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | claimed |
| WO-2007070683-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-8871768-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130324549-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-8445495-B2 | Certain Chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-7825120-B2 | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas | CYTOKINETICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100029680-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20090247544-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2009-10-01 | — | — | US | disclosed |
| EP-1959960-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070197505-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197504-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007089336-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
| WO-2007075377-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007070683-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161617-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | NAMPT 3645/4885PIK3CA 4067/4885PIK3CD 2975/4885 |
| US-20070197505-A1 | Certain chemical entities, compositions and methods | TNNC1, TNNI3, TNNT2 | NAMPT 2884/4885PIK3CA 2144/4885PIK3CD 2476/4885 |
| US-20070197504-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | NAMPT 3645/4885PIK3CA 4067/4885PIK3CD 2975/4885 |
| US-20130324549-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNI3, TNNT2, MYLK2 | NAMPT 3645/4885PIK3CA 4067/4885PIK3CD 2975/4885 |
| US-20100029680-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, MYLK2 | NAMPT 3645/4885PIK3CA 4067/4885PIK3CD 2975/4885 |
| US-20090247544-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | NAMPT 2884/4885PIK3CA 2144/4885PIK3CD 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.